Wednesday, May 2, 2018

On the Record


"What is of note, however, is the discrepancy we see in statin treatment and adherence rates between genders."

— Sharon Jhawar, Pharm.D., chief pharmacy officer at SCAN Health Plan, explaining to Radar on Drug Benefits how her plan’s experience validated recent research finding persistent gender bias when it comes to statin therapy.

No comments:

Post a Comment